MyPal Support Program

OTHER-CARDIOLOGY-TOPICS

CARDIOLOGY

The ACS story aims to reinforce the 2019 ESC/EAS guidelines recommendations and drive urgency to treat patients who just had their ACS.
Please explore the 4 mini scientific campaign below to learn more on how to implement the guidelines recommendations and achieve higher clinical benefits for your patient

Determining the CV risk of your patients can be complex, especially when taking into consideration multiple risk factor

Identify Your Patient

Bringing Dyslipidemia Management guidelines into practice for your very high-CV risk patients

ESC/EAS Guidelines

After their first ACS event, patients are classified as very high CV risk by ESC/EAS 2019 guidelines, regardless of comorbidities

Treat Early

A pioneering program aiming to improve patient outcomes by identifying opportunities to optimize the current post-ACS patient pathway

ACS EuroPath Project

Act Now for your ACS Patients

How to Inject Praluent 75/150 mg Pen?

Empower your patients with this comprehensive educational video on how to inject Praluent 75/150 mg. Designed for healthcare professionals to support their patients, this step-by-step guide ensures an easy and effective injection process. Enhance your practice with this valuable resource.

Why Praluent is the Optimal Choice for Post-ACS Patients?

Explore the compelling reasons why Praluent should be your first choice for patients with recent acute coronary syndrome who need to achieve their LDL-C goals. This informative video provides in-depth clinical insights and evidence, detailing how Praluent’s unique mechanism of action and proven efficacy can significantly improve patient outcomes. The video also covers tips on the 3 main factors: efficacy, safety, and administration to help you to integrate Praluent into your treatment plans. Enhance patient outcomes and elevate your practice with Praluent.

<h2>556/146 for Lipid Management after ACS</h2>
Gain deeper insights into the innovative concept of 556/146, this project aligns with the ESC/EAS 2019 dyslipidemia guidelines, which recommend that post-ACS (Acute Coronary Syndrome) patients achieve an LDL-C value of less than 55 mg/dL (1.4 mmol/L). Lipid levels should be reassessed 4-6 weeks after an ACS event, and if the target is not met, lipid-lowering treatments should be adjusted accordingly.
Through four comprehensive video episodes, we will explore the importance of these targets and the steps necessary to achieve them.

A video explaining the concept of 556/146. Featuring all 3 experts: Prof. A. Catapano, Prof. F. Schiele, Prof. A. Zaman.

Episode #1

A video exploring the concept of 556/146. Featuring all 3 experts: Dr. M. Villaceque, Prof. A. Sionis, Prof. R. De Caterina.

Episode #2

A video with focused insights on 556 concept and why it’s important to achieve LDL-C targets for post-ACS patients.

Episode #3

A video with focused insights on 146 concept and why it’s important to re-evaluate lipid levels within 4-6 weeks for post-ACS patients.

Episode #4

556/146 for Lipid Management after ACS

Are You Ready for 556? Achieving Critical LDL-C Targets

Dive deep into the “556” aspect of the 556/146 concept with this focused video. Learn about the importance of achieving an LDL-C target of &lt;55 mg/dL for post-ACS patients and the steps necessary to reach this critical goal. This video will guide you through the guidelines, the significance of re-evaluating lipid levels within 4-6 weeks, and the adjustments needed if targets are not met. Enhance your knowledge and ensure your patients are on the path to optimal health with these essential insights.

Are You Ready for 146? Achieving Optimal LDL-C Levels

Get ready to understand the “146” aspect of the 556/146 concept in this informative video. Learn about the importance of reaching an LDL-C target of &lt;1.4 mmol/L (55 mg/dL) for post-ACS patients and the critical steps needed to re-evaluate lipid levels within 4-6 weeks. This video will guide you through the necessary adjustments in lipid-lowering treatments to ensure optimal patient outcomes. Stay informed and prepared to implement these guidelines effectively in your practice.

<h2>About The Program</h2>
My Pal Coach Patient Support Program, is aiming to support your patients while taking Praluent medication by providing them with additional support from&nbsp;Patient Call Center
<ul>
 <li>Support on medication injection &amp; responding to patients' FAQs</li>
 <li>Refill follow-up and injection call reminders</li>
</ul>

Register in one step and we will get back to you with more info

<h2>Enrollment Process</h2>
Enrollment in the program
If the patient agrees to receive the services offered by the My Pal Coach, then

<h3>Duration and services methodology</h3>

<h2>Materials</h2>
<h3>Materials that will support you and your patients:</h3>
<h4>HCP Leaflet</h4>
Download the leaflet summarizing the Program details and enrollment process and share it with your peers

<h4>Patient QR Code</h4>
Download patient QR Code and share it with your patients to enroll in the Program

How to Inject Praluent Once-Monthly 300 mg Pen?

Support your patients with this detailed instructional video on using the Praluent once-monthly 300 mg pre-filled pen. Tailored for healthcare professionals, this step-by-step guide ensures patients can confidently and correctly administer their medication. Enhance patient care with this essential resource.

Understanding the 556/146 Concept: Insights from Leading Experts

Join renowned experts Prof. A. Catapano, Prof. F. Schiele, and Prof. A. Zaman as they dive into the innovative 556/146 concept. This video provides a comprehensive explanation of the guidelines recommending an LDL-C target of &lt;55 mg/dL (1.4 mmol/L) for post-ACS patients and the importance of re-evaluating lipid levels within 4-6 weeks. Learn how these targets can significantly impact patient outcomes and the steps necessary to achieve them. Enhance your understanding and stay updated with the latest in dyslipidemia management.

Exploring the 556/146 Concept: Insights from Leading Experts

Dive into the detailed explanation of the 556/146 concept with insights from Dr. M. Villaceque, Prof. A. Sionis, and Prof. R. De Caterina. This video highlights the ESC/EAS 2019 dyslipidemia guidelines, emphasizing the importance of achieving an LDL-C target of &lt;55 mg/dL (1.4 mmol/L) for patients after an acute coronary syndrome (ACS). Understand the critical need for re-evaluating lipid levels within 4-6 weeks and the steps required to adjust treatments if targets are not met. Stay informed with expert perspectives on optimizing patient care in dyslipidemia management.

To read the full content, activate your Sanofi Campus account. Please confirm your email address in the email you received.

If you didn't receive our first email at {email} to confirm your account you can request a new one below. If you don't see it, you may need to check your spam folder.

This information will only be used to validate your account and will not be distributed.

title

Before starting exploring, we can suggest you specific and relevant content

Title

This website is for healthcare professionals only

Welcome to BP Sanofi Campus

Create new password

To offer you a personalised experience, you must

Your profile is incomplete

The ADCT gives a measure of how controlled the eczema is. Answer these 6 simple questions with your patient to find the ADCT score. It will indicate proper course of action.

Atopic dermatitis, a type of eczema, may be affecting your Patient's life in more ways than you know.

Take the Atopic Dermatitis Control Test (ADCT)

Enjoy more exclusive content{newline}by <a>registering today</a>

Already have an account? <a>Sign in here</a>

Best practices on optimising patient care

Get a customised view of the topics that you're interested in, along with the ability to save content to watch or read at a later date.

Unlimited access to premier content, white papers, case studies, research papers, webinars, training, and up-to-date scientific medical resources.

Personalised content based on your areas of interest

Connect and stay up-to-date with peers in your area of speciality and topics of interest through free events and leadership forums.

Please sign in to continue and read the full article

Please sign up to continue reading the full article.

We respect your privacy and will not share your information with any 3rd parties.

Topical guides written specifically for patients

Unlimited access to the latest patient guide guides and resources. Share content with your patients with easy-to-use online tools.

Please complete your profile to read the content.

Your profile is not validated yet. Please verify your inbox.

Restricted Access

We can't find the page you're looking for

You are going to a website that is not operated by Sanofi. Sanofi has no control over the content or availability of linked sites or resources, and accepts no liability or responsibility for them or for any loss or damage that may arise from your use of them. Please ensure that you read the legal and privacy policy sections of any third-party site to which you link.

You are about to leave Sanofi Campus website.

You are now leaving this site to visit a partner website.

Thank you for visiting COPD Sanofi Campus.

This website is for healthcare professionals only.

Welcome to COPD Sanofi Campus.

Welcome to COPD Sanofi Campus

Welcome to CSU Sanofi Campus

Please refresh the page to access the content

Sorry, something went wrong

We're usually a treasure chest of knowledge, but we couldn't find what you're looking for.

We were unable to find what you're searching for

You are about to leave Campus.sanofi/uk.

Images from <a>iStockphoto.com</a>, Fotolia.de, <c>gettyimages.de</c>, <d>pexels.com</d> and <e>photocase.de</e> were used for our websites.

Thank you for registering. Before we get started, we need to confirm your email address to ensure that we have the correct information.

Please follow these steps to complete your registration:

Would you like to receive future text messages about Beyfortus updates?

Sanofi is here to help support your patients, their families, and caregivers. For more information regarding Beyfortus® (nirsevimab-alip), call <a.callPhoneNumberBeyfortus>1-855-BEYFORTUS (1-855-239-3678)</a.callPhoneNumberBeyfortus> or sign up below to receive the latest updates via email or text. All fields are required.

Would you like to learn more about Beyfortus® (nirsevimab-alip) 50 mg and 100 mg injection? Leave us your contact details, and a Sanofi representative will be in touch. All fields are required.

Would you also like to receive future messages and updates about Beyfortus?

Do you want to participate in the Beyfortus Reservation Program?

What information are you interested in learning more about? (Optional)

Are you enrolled in CENRIFKI REMS?

Request a visit from your local ALPROLIX representative to learn more. Call <a.callPhoneNumberAltuviiio>1-800-745-4447</a.callPhoneNumberAltuviiio>, Option 5, or complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>. All fields are required.

Request a visit from your local ALTUVIIIO representative to learn more. Call <a.callPhoneNumberAltuviiio>1-800-745-4447</a.callPhoneNumberAltuviiio>, Option 5, or complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>. All fields are required.

Request a visit from your local QFITLIA representative to learn more. Call <a.callPhoneNumberAltuviiio>1-800-745-4447</a.callPhoneNumberAltuviiio>, Option 5, or complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>. All fields are required.

Sign up to schedule an office visit with your ALPROLIX® Representative or receive updates about ALPROLIX. Please complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>. All fields are required.

Sign up to schedule an office visit with your local Sanofi representative and/or to receive updates about Qfitlia. Please complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>. All fields are required (unless otherwise specified).

All fields are required. (unless otherwise specified)

This site is intended for healthcare professionals only and contains information on Sanofi medicines, educational resources and more. Please click the appropriate button below. By entering this site, you are confirming that you are a healthcare professional. This site contains promotional information. Please note that some of the content on the website is only relevant for HCPs.

Welcome to Sanofi Campus

Welcome to ITP Sanofi Campus

This content is only available to registered users. Please sign in or register to view this content.

Please Sign In

Email verification

You're seeing a preview of the portal. Clear your cookies (by closing your browser window for example) to go back to public mode.

We've updated our privacy notice to better protect your data and enhance your experience. Please take a moment to review the changes by <privacyNewTab>clicking here</privacyNewTab>. Your privacy matters for us. Please click on continue to confirm you have read the new privacy notice.

Privacy Notice Update

Communication consent

My consents

Password

Confirm password

{resultsCount, plural, one {result} other {results}}

Please log in to access to the results

You need to sign-in to your account in order to access medical content.

Please Log In

To access the results, please register in under 1 minute

You are now leaving the Sanofi content section of our site and entering the external medical bibliographic search content section.

You are entering to the External Scientific Content Site

You are now leaving the external medical bibliographic search section of our site and entering the Sanofi content section.

Other Cardiology Topics

Latest Resources

MyPal Support Program

Act Now for your ACS Patients

How to Inject Praluent 75/150 mg Pen?

Why Praluent is the Optimal Choice for Post-ACS Patients?

556/146 for Lipid Management after ACS

Are You Ready for 556? Achieving Critical LDL-C Targets

Are You Ready for 146? Achieving Optimal LDL-C Levels

MyPal Support Program

How to Inject Praluent Once-Monthly 300 mg Pen?

Understanding the 556/146 Concept: Insights from Leading Experts

Exploring the 556/146 Concept: Insights from Leading Experts